Source Articles
VEGF mAb
Showing 16 study arms
with grade ≥3 adverse event data (treatment-related and RT-related).
Click a column header to sort.
Note on patient counts: some articles reported only percentages rather
than absolute numbers. Where this occurred, the number of patients — including those with
grade ≥3 adverse events — was derived by applying the reported percentage to the total arm
size, which may produce a non-integer value. These figures have been rounded to the nearest
integer for display.
| 1st Author | Year | Study Type | Title | DOI | clinical trial number | number of patients | median/mean age | median follow-up [months] | tumor type | treatment setting | drug group | drug name | if other, please specify | number of SBRT courses | intracranial / extracranial | treated site | If other treated site, please specify | median/mean total RT dose [Gy] | minimum total RT dose [Gy] | maximum total RT dose [Gy] | median/mean number of fractions | minimum number of fractions | maximum number of fractions | median/mean dose per fraction [Gy] | minimum dose per fraction [Gy] | maximum dose per fraction [Gy] | toxicity type | patients with acute G>=3 toxicity | patients with late G>=3 toxicity | patients with G>=3 toxicity, timing unspecified | G>=3 AEs | patients with G>=3 AEs | details on G>=3 toxicity | details on G>=3 toxicity in RT field |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Looman et al. | 2026 | Prospective | Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy | 10.1001/jamanetworkopen.2025.53809 | — | 7 | 62 | 18 | Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Head and neck cancer, Esophagus cancer, Melanoma, Kidney cancer, Bladder cancer, Sarcoma, other | oligometastatic, metastatic | VEGF mAb | Bevacizumab, Ramucirumab | — | Missing | intra-cranial | brain | — | — | — | — | Missing | 1 | 10 | — | — | — | RT-related | — | — | 0 | — | — |
—
|
—
|
| Looman et al. | 2026 | Prospective | Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy | 10.1001/jamanetworkopen.2025.53809 | — | 3 | 62 | 18 | Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Head and neck cancer, Esophagus cancer, Melanoma, Kidney cancer, Bladder cancer, Sarcoma, other | oligometastatic, metastatic | VEGF mAb | Bevacizumab | — | Missing | extra-cranial | lung | — | — | — | — | Missing | 1 | 10 | — | — | — | RT-related | — | — | 0 | — | — |
—
|
—
|
| Looman et al. | 2026 | Prospective | Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy | 10.1001/jamanetworkopen.2025.53809 | — | 6 | 62 | 18 | Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Head and neck cancer, Esophagus cancer, Melanoma, Kidney cancer, Bladder cancer, Sarcoma, other | oligometastatic, metastatic | VEGF mAb | Bevacizumab | — | Missing | extra-cranial | other | Abdomen | — | — | — | Missing | 1 | 10 | — | — | — | RT-related | — | — | 0 | — | — |
—
|
—
|
| Novak Filho et al. | 2025 | Retrospective | Radiosurgery for recurrent high-grade gliomas: a critical analysis based on a retrospective single-center series | 10.1007/s10143-025-03907-1 | — | 23 | 51 | 13 | brain | N/A | VEGF mAb | Bevacizumab | — | 43 | intra-cranial | brain | — | Missing | 12 | 24 | 1 | 1 | 1 | Missing | 12 | 24 | Radiation necrosis | — | — | 0 | — | — |
—
|
—
|
| Zheng et al. | 2025 | Prospective | Efficacy and safety of online adaptive magnetic resonance-guided fractionated stereotactic radiotherapy for brain metastases in non-small cell lung cancer (GASTO-1075): a single-arm, phase 2 trial. | 10.1016/j.eclinm.2025.103189 | NCT04946019 | 27 | 58 | 22.3 | Lung cancer | metastatic | VEGF mAb | Bevacizumab | — | Missing | intra-cranial | brain | — | 30 | 30 | 30 | 5 | 5 | 5 | 6 | 6 | 6 | Treatment-rel. | — | — | 0 | — | — |
—
|
—
|
| Zhou et al. | 2025 | Prospective | Efficacy and safety of combining bevacizumab and fractionated stereotactic radiotherapy for extensive brain metastases in patients with non-small cell lung cancer: a prospective phase II study (GASTO-1053) | 10.1002/cac2.70078 | — | 100 | 59 | 35.8 | Lung cancer | oligometastatic, metastatic | VEGF mAb | Bevacizumab | — | Missing | intra-cranial | brain | — | Missing | 30 | 40 | Missing | 5 | 10 | Missing | 4 | 6 | Treatment-rel. | — | — | 0 | — | — |
—
|
—
|
| Wang et al. | 2024 | Retrospective | Outcomes of 2-SSRS plus bevacizumab therapy strategy for brainstem metastases (BSM) over 2 cm(3): a multi-center study | 10.1007/s10143-024-02369-1 | — | 53 | 61 | 18.4 | Breast cancer, Lung cancer, other | metastatic | VEGF mAb | Bevacizumab | — | 63 | intra-cranial | brain | — | 23.5 | Missing | Missing | 2 | 2 | 2 | Missing | 10 | 13 | Treatment-rel. | 0 | — | — | — | — |
—
|
—
|
| Zhang et al. | 2024 | Retrospective | Bevacizumab reduces cerebral radiation necrosis due to stereotactic radiotherapy in non-small cell lung cancer patients with brain metastases: an inverse probability of treatment weighting analysis. | 10.3389/fimmu.2024.1399613 | — | 28 | 65.5 | 60.6 | Lung cancer | oligometastatic, metastatic | VEGF mAb | Bevacizumab | — | Missing | intra-cranial | brain | — | Missing | 18 | 30 | Missing | 1 | 5 | Missing | 5 | 24 | Treatment-rel. | 3 | 0 | — | acute G3: 3 AEs | acute G3: 3 pts |
acute G3: Leukopenia, neutropenia
|
—
|
| Wang et al. | 2023 | Retrospective | Efficacy and safety of a "sandwich therapy" based on staged stereotactic radiosurgery and bevacizumab for large brainstem metastases | 10.1016/j.clineuro.2023.107911 | — | 42 | 66.5 | Missing | Breast cancer, Lung cancer, other | oligometastatic, metastatic | VEGF mAb | Bevacizumab | — | Missing | intra-cranial | brain | — | 25 | Missing | Missing | 2 | 2 | 2 | Missing | 11 | 15 | RT-related | — | 2 | — | acute G2-3: 8 AEs, late G3: 1 AE, late G5: 1 AE | acute G2-3: 6 pts, late G3: 1 pt, late G5: 1 pt |
acute G2-3: nausea, headache, ataxia deterioration, late G3: Cerebral radiation necrosis, late G5: Cerebral radiation necrosis
|
—
|
| Chen et al. | 2021 | Retrospective | Peri-radiosurgical administration of bevacizumab improves radiographic response to single and fractionated stereotactic radiosurgery for large brain metastasis | 10.1007/s11060-021-03782-y | — | 49 | Missing | 27.6 | Breast cancer, Lung cancer, other | oligometastatic, metastatic | VEGF mAb | Bevacizumab | — | Missing | intra-cranial | brain | — | 51.3 | 28 | 60 | 3 | 1 | 5 | 27 | 20 | 35 | Treatment-rel. | — | — | 4 | any G3: 4 AEs | any G3: 4 pts |
any G3: hypertension
|
/
|
| Kroeze et al. | 2021 | Retrospective | Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the 'TOaSTT' database | 10.1186/s13014-020-01730-0 | — | 9 | 63 | 18.7 | Lung cancer | metastatic | VEGF mAb | Missing | — | 192 | any | brain, lung, liver, adrenal gland, bone, LN unspecified, other | Soft tissue (whole group) | Missing | Missing | Missing | Missing | 1 | 5 | Missing | Missing | Missing | RT-related | 1 | 0 | — | acute G3: 1 AE | acute G3: 1 pt |
acute G3: headache
|
—
|
| Guan et al. | 2020 | Prospective | Hypofractionated Radiosurgery Plus Bevacizumab for Locally Recurrent Brain Metastasis with Previously High-Dose Irradiation | 10.1016/j.wneu.2019.08.233 | Missing | 24 | 58 | 13.5 | Breast cancer, Lung cancer, other | oligometastatic, metastatic | VEGF mAb | Bevacizumab | — | Missing | intra-cranial | brain | — | Missing | 9.5 | 29 | Missing | 2 | 5 | Missing | Missing | Missing | Treatment-rel. | 1 | — | — | acute G3: 2 AEs | acute G3: 1 pt |
acute G3: fatigue and headache
|
acute G3: fatigue and headache
|
| Clarke et al. | 2017 | Prospective | Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma | 10.1016/j.ijrobp.2017.06.2466 | NCT01392209 | 12 | 63 | — | brain | any | VEGF mAb | Bevacizumab | — | 12 | intra-cranial | brain | — | 30 | 27 | 33 | 3 | 3 | 3 | 10 | 9 | 11 | RT-related | — | — | 1 | any G3: 1 AE | any G3: 1 pt |
any G3: fatigue and cognitive deterioration
|
any G3: fatigue and cognitive deterioration
|
| Guinde et al. | 2017 | Retrospective | Bevacizumab Plus Radiosurgery for Nonsquamous Non-Small Cell Lung Cancer Patients with Brain Metastases: Safe Combination? | 10.1016/j.wneu.2017.07.185 | — | 6 | 58, 5 | 7, 8 | Lung cancer | metastatic | VEGF mAb | Bevacizumab | — | 40 | intra-cranial | brain | — | 20, 1 | Missing | Missing | Missing | Missing | Missing | Missing | Missing | Missing | Treatment-rel. | 0 | — | — | — | — |
—
|
—
|
| Yomo et al. | 2016 | Retrospective | Salvage stereotactic radiosurgery with adjuvant use of bevacizumab for heavily treated recurrent brain metastases: a preliminary report | 10.1007/s11060-015-2019-3 | — | 5 | 68 | 4.5 | Lung cancer | oligometastatic, metastatic | VEGF mAb | Bevacizumab | — | 5 | intra-cranial | brain | — | 18 Gy @50% | 15 Gy @70% | 20 Gy @50% | 1 | 1 | 1 | 18 Gy @50% | 15 Gy @70% | 20 Gy @50% | Treatment-rel. | — | — | 2 | any G3: 2 AEs | any G3: 2 pts |
any G3: Anemia, GI bleeding
|
—
|
| Conde-Moreno et al. | 2015 | Retrospective | Fractionated stereotactic radiotherapy plus bevacizumab after response to bevacizumab plus irinotecan as a rescue treatment for high-grade gliomas | 10.1016/j.rpor.2015.01.004 | — | 9 | 54.8 | 38 | brain | — | VEGF mAb | Bevacizumab | — | 9 | intra-cranial | brain | — | 30 | — | — | 6 | — | — | 5 | — | — | Treatment-rel. | 0 | 0 | 0 | — | — |
—
|
—
|